Dynavax to Announce Q2 2025 Results on August 7, Host Call
Dynavax Technologies Corporation, a biopharmaceutical company based in Emeryville, California, will release its second quarter 2025 financial results on August 7, 2025, after the close of U.S. financial markets. This announcement marks a key moment for the company as it continues to innovate in the vaccine sector.
Following the financial results announcement, Dynavax will host a conference call and live audio webcast at 16:30 ET (13:30 PT) on the same day. Investors and analysts can access the live audio webcast through the “Events & Presentations” section of the company’s website at https://investors.dynavax.com/events-presentations. A replay of the webcast will be available for 30 days after the event, allowing for greater access to the disclosed information.
Participants wishing to join the conference call must register using a specific caller registration link. It is advisable for attendees to log in approximately 10 minutes prior to the start of the call to ensure connectivity.
About Dynavax Technologies Corporation
Dynavax is dedicated to developing and commercializing innovative vaccines aimed at protecting against infectious diseases. The company has two primary commercial products: the HEPLISAV-B ® vaccine, which is approved in the United States, the European Union, and the United Kingdom. This vaccine is designed to prevent infections caused by all known subtypes of the hepatitis B virus in adults aged 18 and older. Additionally, Dynavax produces the CpG 1018 ® adjuvant, which is employed in HEPLISAV-B and various adjuvanted COVID-19 vaccines.
For further details on their marketed products and ongoing development pipeline, interested parties can visit the official website at www.dynavax.com.
For media inquiries, Paul Cox can be reached at [email protected] or by phone at 510-665-0499, while Nicole Arndt is available at [email protected] or 510-665-7264.
